Plasma protein fractionation by sequential polyacid precipitation
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 18, 2017
Issued Date -
N/A
app pub date -
Sep 14, 2012
filing date -
Sep 16, 2011
priority date (Note) -
In Force
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Patent Longevity
|
Forward Citations
|
Abstract
There is a recognized need for novel, more simplified, approaches to isolation of plasma from whole blood, as well as a need to isolate cell-free plasma fractions containing different plasma proteins. Methods are divulged for use of aqueous phase systems, formed in blood or blood containing solutions via addition of a single polymer at relatively low concentration, to effect isolation (clarification) of plasma proteins from blood cells. Methods are also divulged to replace widely used Cohn-type plasma protein fractionation which is based on sequential addition of up to 40% (v/v) ethanol and other precipitants, with simple sequential addition of a polyacid. The latter results in isolation of plasma protein fractions (i.e. fibrinogen, immunoglobulin, albumin) in sequence similar to that obtained with Cohn Fractionation and therefore may be suitable for use to reduce solvent use and solvent-related process complications in existing plasma protein purification processes. It may also support use of polymeric film based containers in novel solvent free plasma fractionation processes. The methods disclosed may also be suitable for use in smaller scale plasma protein isolation, in research and diagnostic applications. The general methodologies are robust and can function over a broad range of process variables such as temperature and pH.
First Claim
all claims..Other Claims data not available
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
CYTIVA BIOPROCESS R&D AB | 751 84 UPPSALA |
International Classification(s)

- 2012 Application Filing Year
- A61K Class
- 11964 Applications Filed
- 9694 Patents Issued To-Date
- 81.03 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Berg, Mikael | Uppsala, SE | 9 | 14 |
# of filed Patents : 9 Total Citations : 14 | |||
Kjorning, Johanna | Stockholm, SE | 1 | 5 |
# of filed Patents : 1 Total Citations : 5 | |||
Shanagar, Jamil | Uppsala, SE | 8 | 41 |
# of filed Patents : 8 Total Citations : 41 | |||
Van, Alstine James | Uppsala, SE | 20 | 246 |
# of filed Patents : 20 Total Citations : 246 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
- 1 Citation Count
- A61K Class
- 45.09 % this patent is cited more than
- 8 Age
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|---|---|---|---|
11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Oct 18, 2028 |
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events
Date | Code | Event | Description |
---|---|---|---|
Oct 02, 2024 | MAFP | MAINTENANCE FEE PAYMENT | free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY year of fee payment: 8 |
Sep 18, 2020 | MAFP | MAINTENANCE FEE PAYMENT | free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY year of fee payment: 4 |
Jun 17, 2020 | AS | ASSIGNMENT | free format text: CHANGE OF NAME;ASSIGNOR:GE HEALTHCARE BIOPROCESS R&D AB;REEL/FRAME:054299/0349 Owner name: CYTIVA BIOPROCESS R&D AB, SWEDEN Effective Date: Jun 17, 2020 |
Apr 18, 2017 | I | Issuance | |
Mar 29, 2017 | STCF | INFORMATION ON STATUS: PATENT GRANT | free format text: PATENTED CASE |
Dec 18, 2015 | AS | ASSIGNMENT | free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GE HEALTHCARE BIO-SCIENCES AB;REEL/FRAME:038811/0001 Owner name: GE HEALTHCARE BIOPROCESS R&D AB, SWEDEN Effective Date: Dec 18, 2015 |
Nov 20, 2014 | P | Published | |
Mar 17, 2014 | AS | ASSIGNMENT | free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN ALSTINE, JAMES;BERG, MIKAEL;SHANAGAR, JAMIL;AND OTHERS;SIGNING DATES FROM 20120919 TO 20120928;REEL/FRAME:032452/0716 Owner name: GE HEALTHCARE BIO-SCIENCES AB, SWEDEN |
Sep 14, 2012 | F | Filing | |
Sep 16, 2011 | PD | Priority Date |

Matter Detail

Renewals Detail
